Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab long-term safety extension in wet AMD
NL-OMON31158Phase 4Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Novartis. Primary endpoint: Incidence and severity of ocular and non-ocular adverse events. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on NL-OMON31158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31158.